Optimal Management of Refractory Crohn's Disease: Current Landscape and Future Direction

被引:1
|
作者
Lee, Kate E. [1 ]
Tu, Violet Y. [1 ]
Faye, Adam S. [2 ,3 ]
机构
[1] Duke Univ, Sch Med, Dept Med, Durham, NC USA
[2] NYU, Sch Med, Dept Gastroenterol, New York, NY 10016 USA
[3] NYU, NYU Langone Div Gastroenterol, Med & Populat Hlth, 303 East 33rd St, New York, NY 10016 USA
关键词
Crohn's disease; surgery; advanced therapies; biologics; INFLAMMATORY-BOWEL-DISEASE; FECAL MICROBIOTA TRANSPLANTATION; ENTERAL NUTRITION; CLINICAL-RESPONSE; DOSE-ESCALATION; DOUBLE-BLIND; INFLIXIMAB; REMISSION; THERAPY; METAANALYSIS;
D O I
10.2147/CEG.S359376
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Refractory Crohn's disease, defined as ongoing inflammation despite the trial of multiple advanced therapies, impacts a number of individuals with Crohn's disease, and leads to significant burden in quality of life and cost. Interventions such as early implementation of advanced therapies, optimization of current therapies prior to switching to an alternative, as well as understanding the overlapping pathophysiology between immune-mediated disorders, however, can help shift the current landscape and reduce the number of patients with refractory disease. As such, in this review we summarize the key takeaways of the latest research in the management of moderate-to-severe Crohn's disease, focusing on maximization of our currently available medications, while also exploring topics such as combination advanced therapies. We also describe evidence for emerging and alternative therapeutic modalities, including fecal microbiota transplant, exclusive enteral feeding, hyperbaric oxygen, stem cell therapy, bone marrow transplant, and posaconazole, with a focus on both the potential impact and specific indications for each.
引用
收藏
页码:75 / 86
页数:12
相关论文
共 50 条
  • [21] Current landscape and the future direction of open access publishing
    Heber, Joerg
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 253
  • [22] Optimal Management of Crohn's Disease after intestinal Resection
    Reibetanz, J.
    Germer, C. T.
    CHIRURG, 2015, 86 (11): : 1070 - 1070
  • [23] Current and future management of Alzheimer's disease
    Gauthier, Serge
    Poirier, Judes
    ALZHEIMERS & DEMENTIA, 2008, 4 (01) : S48 - S50
  • [24] Upadacitinib for Refractory Crohn's Disease
    Riggs, Taylor A.
    Neimann, Adam
    Horst, Sara N.
    Dalal, Robin L.
    Scoville, Elizabeth
    Pabla, Baldeep
    Beaulieu, Dawn B.
    Schwartz, David A.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S619 - S620
  • [25] Methotrexate in refractory Crohn's disease
    Vandeputte, L
    D'Haens, G
    Baert, F
    Rutgeerts, P
    INFLAMMATORY BOWEL DISEASES, 1999, 5 (01) : 11 - 15
  • [26] Risankizumab for Refractory Crohn's Disease
    Bhachawat, Neal K.
    Garza, Manuel
    Saleh, Adam
    Glassner, Kerri
    Abraham, Bincy
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (12S): : S30 - S30
  • [27] Perioperative management of ileocecal Crohn's disease in the current era
    Yamamoto, Takayuki
    Lightner, Amy Lee
    Spinelli, Antonino
    Kotze, Paulo Gustavo
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2020, 14 (09) : 843 - 855
  • [28] Current review of the management of fistulising perianal Crohn's disease
    Adegbola, Samuel O.
    Sahnan, Kapil
    Twum-Barima, Charlene
    Iqbal, Nusrat
    Reza, Lillian
    Lung, Phillip
    Warusavitarne, Janindra
    Tozer, Phil
    Hart, Ailsa
    FRONTLINE GASTROENTEROLOGY, 2021, 12 (06) : 515 - 523
  • [29] MRI in Crohn's disease-current and future clinical applications
    Fiorino, Gionata
    Bonifacio, Cristiana
    Malesci, Alberto
    Balzarini, Luca
    Danese, Silvio
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2012, 9 (01) : 23 - 31
  • [30] CT and MR enterography in Crohn’s disease: current and future applications
    David H. Bruining
    Gauraang Bhatnagar
    Jordi Rimola
    Stuart Taylor
    Ellen M. Zimmermann
    Joel G. Fletcher
    Abdominal Imaging, 2015, 40 : 965 - 974